Kornimate/medical-research-clean huggingface dataset:
pain neuroscience education in patients with total knee arthroplasty

Conditions: Osteoarthritis, Knee

Summary: the aim of pain neuroscience education (pne) is to explain to patients the biological and physiological processes involved in a pain experience and, more importantly, defocus the issues associated with the anatomical structures. pne provides compelling evidence in reducing pain, disability, pain catastrophization, and limited physical movement in musculoskeletal problems. knee osteoarthritis (koa) is a very common painful musculoskeletal problem, especially in people over 50 years old, and lead to decrease in knee range of motion. despite costly arthroscopic surgeries and long-term physiotherapy treatments, poor outcomes are common. the lack of satisfactory results suggests that some practices should be revised. although pne could be useful as an intervention, to our knowledge, there is no randomized controlled trial in the literature investigating the effects of pne in patients with a koa. therefore, we aimed to examine the effectiveness of pne on clinical outcomes in patients with koa.


Eligibility criteria:
inclusion criteria: * having a body mass index between 19-40 kg/m2, * having had a unilateral tka, * knee pain score to be 4 and above daily according to the visual analog scale, * ability to read, speak and understand turkish. exclusion criteria: * prosthesis disorders requiring re-surgery, * having visual, auditory and cognitive impairment, * secondary tka such as rheumatoid arthritis, * acute pain, * pregnancy, drug and alcohol use, * having bilateral tka, * not volunteering to participate in the study

Keywords: pain neuroscience education knee osteoarthritis
nd:yag laser hyaloidotomy for premacular hemorrhage in diabetic eyes

Conditions: Proliferative Diabetic Retinopathy

Summary: premacular subhyaloid hemorrhage is a sudden profound loss of vision in eyes with proliferative diabetic retinopathy (pdr). pars plana vitrectomy is the treatment of choice for premacular hemorrhage in eyes with proliferative changes. nd:yag laser hyaloidotomy has been used to evacuate the premacular hemorrhage


Eligibility criteria:
inclusion criteria: * eyes with premacular subhyaloid hemorrhage of more than 3 disc diameters, involving the fovea. * eyes with proliferative diabetic retinopathy exclusion criteria: * dense media opacity (corneal/cataract) * patients with bleeding tendency or on anti-coagulant drugs
implementation of liquid biopsies during routine clinical care in patients with advanced malignancies (liqplat)

Conditions: Advanced Solid Tumor

Summary: the goal of this study is to assess the implementation and feasibility of ctdna measurements from blood samples obtained during routine clinical care of cancer patients in the university hospital basel. researchers will compare clinical and patient reported outcomes from the liqplat study with patients who did not receive ctdna measurements (external comparator from registry ao_2023-00091). blood samples will be drawn from the patients as part of routine care and ctdna measurements will be performed on these samples.

liquid biopsies, in particular the analysis of circulating tumor dna (ctdna), have emerged as a promising tool for detecting and monitoring cancer. measuring ctdna in patients with solid malignancies may help to identify targetable alterations, measure disease burden, identify early mutations of resistance, tailor and deescalate cancer treatment, and predict patient prognosis. although the adoption and application of ctdna measurements for patients with solid tumors in routine clinical care is increasing, evidence supporting the integration of ctdna into current practice is limited, especially for patients with advanced cancers. this is a trial using routinely collected health care data from an ongoing registry (ao_2023-00091) in cancer patients with advanced solid malignancies receiving first line systemic anticancer treatment for advanced disease. this trial will assess the feasibility and implementation of routine measurement of ctdna and its association with clinical outcomes, including quality of life and survival. all patients will receive routine diagnostics, treatment and follow-up. all patients with a new cancer diagnosis will be assessed for eligibility based on the routinely collected information available in the registry. we will then randomly decide which eligible patients are invited to participate in the trial. if patients accept the invitation and intend to get a measurement of ctdna, they have to provide written informed consent. results from ctdna analyses will be discussed at the molecular tumor board, an established regular interdisciplinary meeting at the university hospital basel (part of routine care) to discuss patients with complex findings from tumor sequencing analyses. treatment changes occurring during the trial duration will be at the discretion of treating physician and according to patient's preference as is routine standard of care.

Eligibility criteria:
inclusion criteria: * patients with a proven solid malignant disease, i.e. with solid malignant tumors where no primary surgical resection is planned or solid malignant tumors that are locally advanced and inoperable or solid tumors that are metastatic * no prior treatment for advanced/metastatic disease * indication for medical anti-cancer treatment (including combined chemoradiotherapy) as judged by the treating physician * patient age 18 years and older * general research consent of the university hospital basel exclusion criteria: ● patients with primary brain tumors

Keywords: ctdna
study of adaptive radiotherapy for high-grade glioma based on interfraction mri

Conditions: High-grade Glioma

Summary: the changes of target and organs at risk in patients with high-grade glioma during concurrent chemoradiotherapy were evaluated by mri image between radiotherapy fractions.

to prospectively evaluate the changes of target organs and risk organs in patients with high-grade glioma during concurrent chemoradiotherapy.the related factors causing this change are discussed.the relationship between changes and patient survival was analyzed.a predictive model was established to provide individualized adaptive radiotherapy for patients.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years old; 2. high-grade glioma was confirmed by pathology after surgery; 3. ecog score 0-2 points; 4. receiving the standard stupp regimen (i.e. 6 weeks of temozolomide concurrent chemoradiotherapy +6 cycles of temozolomide adjuvant chemotherapy); 5. baseline data available. exclusion criteria: 1. the pathological diagnosis is not clear; 2. no synchronous chemotherapy/adjuvant chemotherapy \&lt; 6 cycles; 3. there are other malignant tumors; 4. previously radiotherapy to the head; 5. interruption of radiotherapy for more than 5 days; 6. failure to collect baseline data.

Keywords: adaptive radiotherapy high-grade glioma mri image
gait analysis in multiple sclerosis patients

Conditions: Multiple Sclerosis; 3D Gait Analysis; Vestibular Rehabilitation

Summary: in the literature, the results of vestibular rehabilitation treatment applied in patients with multiple sclerosis (ms) have been investigated in detail under the headings such as fatigue, physical activity level, and quality of life, and its effects on walking have also been tried to be examined. however, in the studies conducted, gait assessments were made through questionnaires and timed tests, and devices that provide more objective data such as 3-dimensional gait analysis were not used. again, the effects of vestibular rehabilitation programs on dual-task were not examined in previous studies. therefore, the aims of our study are: 1. to determine the effect of individually designed vestibular rehabilitation exercises on the kinetic and kinematic components of walking; 2. to determine the effect of vestibular rehabilitation exercises specially designed for the person on gait parameters during cognitive and motor tasks.


Eligibility criteria:
inclusion criteria: * between aged 25-60 years * diagnosed with ms for at least 5 years * relapsing and progressive ms according to mc donald criteria * edss score of ≤ 3.5 ≤ 6 * modified ashworth scale \< 3 * being eligible to work by a neurologist exclusion criteria: * having had an ms-related attack in the 3 months before the study * changes in medications within 6 months prior to the study * to have participated in the rehabilitation program within 1 month before the study * serious neurological, cardiac, pulmonary, rheumatological, audiovisual, or orthopedic disorders that limit assessments and/or intervention programs

Keywords: gait analysis, multiple sclerosis, vestibular, kinetic, kinematic
randomized trial of trust in online videos about prostate cancer

Conditions: Prostate Cancer

Summary: the study team will evaluate the impact of video characteristics on health consumers' trust in online videos. participants will be randomized to watch a video by one of four speakers about prostate cancer screening or clinical trials and complete a questionnaire (approximately 15 minutes total).


Eligibility criteria:
inclusion criteria: 1. us adult age 40+ 2. enrolled in dynata online survey panel exclusion criteria: 1. children 2. individuals living outside the u.s.

Keywords: trust
ozurdex as adjunct to avastin compared to avastin alone in treatment of patients with diabetic macular edema

Conditions: Diabetic Macular Edema

Summary: the investigators hypothesize that a combination treatment with avastin and ozurdex will result in a more rapid improvement of visual acuity compared to the use of avastin alone.


Eligibility criteria:
inclusion criteria: * male or female age 18 years or older * type 1 or type 2 diabetes * bcva score of \>24 and \<78 letters * presence of dme defined as optical coherence tomography center subfield thickness (oct cst) \>250microns exclusion criteria: * anti-vegf intravitreal treatment in last 4 weeks * intravitreal steroid treatment in the last 8 weeks * prp or focal laser in last 4 months * active iris neovascularization

Keywords: diabetic macular edema dme
effect of prevacid on prostaglandin levels in patient with stress ulcer

Conditions: Stomach Ulcer

Summary: the purpose of this study is to measure the prostaglandin levels in patients with stress ulcer and the effect of prevacid on prostaglandin levels in patients with stress ulcer.

the prostaglandin system plays an important role in the gastric mucosa to strengthen its resistance against injury. critically ill patients are at greatest risk of developing stress-related gastric mucosal lesions. although the levels of prostaglandins in gastric mucosa in patients with stressed animal has been studied, prostaglandin levels in the gastric mucosa in patients with stress ulcer have not been studied and the effect of prevacid on prostaglandin levels in gastric mucosa from patients with stress ulcer is unknown. we hypothesize that prostaglandin levels are low in the gastric mucosa in patients with stress ulcer, and prevacid is an effective agents in increasing prostaglandin levels in the gastric mucosa in stress stress ulcer. comparison(s): the prostaglandin levels in patients who treated with prevacid for stress ulcer, compared to the prostaglandin levels in patients who treated with h2 blocker for stress ulcer.

Eligibility criteria:
inclusion criteria: * patients in icu with documented gastric stress ulcer by endoscopic examination, including patients with h. pylori infection; * patients have no known ulcer within 8 weeks prior to be admitted to icu; * patients not on any ppi for 4 weeks prior to the study; * patients or family be consented for the study. exclusion criteria: * patients have gastric ulcer within 8 weeks prior to be admitted to icu; * patients have gastric cancer confirmed by pathology; * patients on one of the ppis already; * patients on any of the non-steroidal antiinflammatory drugs.

Keywords: gastric stress ulcer prevacid prostaglandin
a study to assess the safety and efficacy of elezanumab when added to standard of care in relapsing forms of multiple sclerosis

Conditions: Multiple Sclerosis (MS)

Summary: the purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with relapsing multiple sclerosis (rms).


Eligibility criteria:
inclusion criteria: * participant has diagnosis of relapsing remitting multiple sclerosis (rrms) or secondary-progressive multiple sclerosis (spms) with relapses within the past 24 months. * participant has cranial magnetic resonance imaging (mri) demonstrating lesion(s) consistent with multiple sclerosis (ms). * participant has evidence of physical disability according to expanded disability status scale (edss) or timed 25-foot walk (t25fw) or 9-hole peg test. exclusion criteria: - participants must not have experienced or be recovering from a clinical ms relapse within 6 months of screening.

Keywords: relapsing multiple sclerosis multiple sclerosis elezanumab abt-555
heterogeneity of diabetes: integrated muli-omics to identify physiologic subphenotypes and evaluate targeted prevention

Conditions: Prediabetes / Type 2 Diabetes

Summary: the study team will invite participants with prediabetes or mild diabetes (hba1c 5.7-7.0) to join a 5-year research study that will define subphenotypes of type 2 diabetes based on underlying physiology (eg insulin resistance, beta-cell dysfunction, incretin defect, liver insulin resistance) and then test the hypothesis that response to three first-line treatments will vary according to metabolic subphenotype. variables of interest include glucose, cardiovascular risk markers, and weight. treatments include mediterranean diet, metformin, and a glp-1 agonist. participants will go through an initial screening, followed by three treatment periods, each lasting 4 months with 3 month washout in-between treatment periods. this study will help us understand how personalized treatments can help control blood glucose, reduce cardiovascular risk, and manage weight. while there may be minor side effects-like slight discomfort from blood tests, gastrointestinal symptoms from some of the medications, and small radiation exposure from dxa body scans-the treatments offered in this study have all been well studied and are known to lower risk for diabetes and cardiovascular disease


Eligibility criteria:
inclusion criteria: * bmi ≥23 (≥22 in asians) kg/m2 but \< 45 kg/m2 * hba1c 5.7-8.0% while not on antihyperglycemic medications exclusion criteria: * recent (\<6mos) cvd event * active malignancy, kidney/liver disease pregnancy/lactation, chronic inflammatory disease, eating disorder, bariatric surgery * history of acute pancreatitis * family or personal history of medullary thyroid cancer * current use of antihyperglycemic, diabetogenic, or weight loss medications (washout allowed if approved by primary physician) * heavy alcohol use * hct \ 1.4, alt\> 3x uln * physical activity \>2 hours/day * inability to come to stanford ctru for metabolic testing
platelet transfusion in acute-on chronic liver failure

Conditions: Acute-On-Chronic Liver Failure

Summary: acute on-chronic liver failure (aclf) is a severe liver disease with a 28-day mortality rate of up to 40%. when the patients get 3 or more organ failures, the 28-day mortality rate is up to 82.6%. though the aclf patients have high short-term mortality, and the only effective treatment method is liver transplantation. however, few patients can be treated due to the scarcity of liver source, rapid disease progression and short transplantation window. our team evaluated the platelet function of 100 patients with aclf by using the thromboelastograghy (teg 5000). it was found for the first time that the reactivity of platelets of aclf patients decreased, and the platelet inhibition rate (especially the adp pathway) was related to patients'short-term prognosis. when the adp inhibition rate was 70%, the patients'28-day mortality was up to 100%. however, the mechanism of low platelet response to adp in aclf patients is still unclear. we found that the platelet function in patients with aclf 2-3 grade and inhibition rate beyond 70% was improved and the 28-day mortality decreased after platelet transfusion. whether platelet transfusion can prolong survival time needs to be determined in a prospective controlled study. therefore, this study is expected to find a new therapeutic method to reduce the mortality of patients with aclf.


Eligibility criteria:
inclusion criteria: * 18-60 years old; * patients with compensated cirrhosis conformed to the (aclf) diagnostic criteria of chronic and acute liver failure defined by the european association of hepatology (easl-clif), and met the aclf-2 and 3 grades. adp inhibition rate ≥ 70%. exclusion criteria: * patients with severe platelet allergy in the past; * coma caused by cerebral hemorrhage or primary diseases of the nervous system; * those who have taken anti-platelet drugs or anticoagulants within four weeks; * rupture and bleeding of evb occurred within 1 week. * those who received platelet transfusion within 1 week; * patients with liver cancer or other malignant tumors; * pregnant and lactating women; * complicated with other serious chronic diseases; * not signing the informed consent form; * other researchers do not consider it appropriate to participate in the study.
tranexamic acid for the prevention of blood loss in high risk delivered women

Conditions: Postpartum Hemorrhage; High Risk Pregnancy; Tranexamic Acid; Third-Stage Postpartum Hemorrhage, With Delivery

Summary: postpartum hemorrhage and its complications are very well known causes for maternal mortality .uterine atony is the most common cause for postpartum hemorrhage

postpartum hemorrhage and its complications are very well known causes for maternal mortality and morbidity especially in developing countries. world health organization recommendations for active management of the third stage of labor (amtsl), on 2012 included the use of uterotonics for the prevention of postpartum hemorrhage (pph) during the third stage of labor for all births. tranexamic acid (ta) is antifibrinolytic agent used to decrease blood loss in surgery and health conditions associated with increased bleeding. a cochrane systematic review from the best available evidence to determine whether ta is effective and safe for preventing pph in comparison to placebo or no treatment the review concluded that ta (in addition to uterotonic medications) decreases blood loss postpartum and prevents pph and blood transfusions following vaginal birth and abdominal delivery in women at low risk of pph based on studies of mixed quality. there was insufficient evidence to draw conclusions about serious side effects and the effects of ta on venous thromboembolic events and mortality beside its use in high-risk women was not investigated on

Eligibility criteria:
inclusion criteria: * age ≥ 18 year. * planed vaginal delivery * grand multiparity * twin pregnancy * polyhydramnios * previous history of pph * macrosomic baby * prolonged labour * hellp syndrome * using of low-molecular weight heparin and asprin during pregnancy. * vaginal birth after cesarean section exclusion criteria: * intrauterine death. * history of thromboembolic disease * current or previous history of heart disease ,renal and liver disorders * history of seizure or epilepsy * placenta previa * placental abruptio
vestibular dysfunction as a cause of chronic nausea & vomiting: a follow up survey

Conditions: Dysfunction of Vestibular System; Nausea Persistent; Vomiting

Summary: the purpose of this study is to characterize the accompanying symptoms, evaluation and management of patients with chronic vestibular dysfunction presenting with nausea and vomiting.

based on prior study, a significant portion of patients referred for refractory gastroparesis in fact have signs suggestive of vestibular dysfunction as the cause of chronic nausea and vomiting. our prior retrospective study identified a population of said subjects. the aim of this study is to further characterize the concomitant symptoms, course of diagnosis, treatment and long-term follow up (up to 5 yrs) of this condition.

Eligibility criteria:
inclusion criteria: * clinical symptoms of nausea and vomiting for at least 4 weeks * abnormal modified fukuda stepping test on examination (\>90 degree rotation from midline while marching in place for 60 seconds) or nystagmus or abnormal rhomberg test exclusion criteria: * pregnancy * unable to complete questionnaire survey
echo-012 kosmos bladder clinical validation study

Conditions: Bladder Disease; Bladder Retention Volume; Bladder Dysfunction; Bladder Function

Summary: the goal of this clinical trial is to compare the kosmos automatic bladder volume to the manual annotated bladder volume in participants across gender (male and female), age (children ages 7-17 and adults 18-89), and bmi strata (low to normal and high bmi). the hypothesis it aims to evaluate is: the pearson correlation coefficient between kosmos estimated bladder volume and manually annotated bladder volume will yield more than 0.90. participants will: * have their full bladders scanned and bladder volume calculated using the kosmos ultrasound diagnositic system by both a nurse and sonographer. * participants will void and measure their urine volume. * participants empty bladders will be scanned and bladder volume calculated using the kosmos ultrasound diagnositic system again by both a nurse and sonographer. * three sonographers will manually annotate the pre- and post-void exam images for each patient to calculate the manually annotated bladder volume.


Eligibility criteria:
inclusion criteria: * read and sign an english consent form, or assent form, in the case of a minor child * read and complete an english demographic and general health survey, or have an lar complete it for them in the case of a minor child * give consent for participation, or assent in the case of a minor child * able and willing to comply with study requirements * follow fluid consumption requirements prior to the study visit * those aged 7 years through 89 years, healthy as well as individuals with pelvic region abnormalities (if applicable), including but not limited to: i) bladder cancer ii) thickened bladder wall iii) bladder stones iv) current bladder or urinary tract infection exclusion criteria: * adults over 89 years old * children under the age of 7 * persons who are pregnant * persons who report an empty bladder upon arrival at their scheduled study visit * children in foster care, as a foster parent may not legally consent for a foster child * those who cannot or refuse to sign their consent or assent (including those with an lar willing to provide consent) * those who cannot provide informed consent or whose lar cannot provide consent * those who cannot speak or read english * participants from echo-010 bladder ai training and validation data collection study